Antares Pharma Inc (NASDAQ:ATRS) Short Interest Update

Antares Pharma Inc (NASDAQ:ATRS) was the recipient of a large decline in short interest during the month of July. As of July 31st, there was short interest totalling 5,482,300 shares, a decline of 16.8% from the June 30th total of 6,586,500 shares. Approximately 3.9% of the company’s shares are sold short. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 4.9 days.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ATRS. Cortina Asset Management LLC grew its position in shares of Antares Pharma by 100.3% in the 2nd quarter. Cortina Asset Management LLC now owns 2,072,605 shares of the specialty pharmaceutical company’s stock valued at $6,819,000 after buying an additional 1,037,675 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Antares Pharma by 10.0% in the 2nd quarter. BlackRock Inc. now owns 10,904,306 shares of the specialty pharmaceutical company’s stock valued at $35,875,000 after purchasing an additional 993,787 shares during the period. Millennium Management LLC lifted its stake in shares of Antares Pharma by 118.2% in the 4th quarter. Millennium Management LLC now owns 1,507,964 shares of the specialty pharmaceutical company’s stock valued at $4,102,000 after purchasing an additional 816,798 shares during the period. Asymmetry Capital Management L.P. acquired a new position in shares of Antares Pharma in the 2nd quarter valued at about $906,000. Finally, Amundi Pioneer Asset Management Inc. acquired a new position in shares of Antares Pharma in the 1st quarter valued at about $730,000. Hedge funds and other institutional investors own 43.10% of the company’s stock.

Shares of NASDAQ ATRS traded up $0.03 during trading on Wednesday, reaching $3.19. The company had a trading volume of 30,945 shares, compared to its average volume of 1,023,430. The company has a fifty day simple moving average of $3.21. Antares Pharma has a 12 month low of $2.53 and a 12 month high of $3.96. The company has a market cap of $533.21 million, a PE ratio of -79.50 and a beta of 0.95. The company has a current ratio of 3.46, a quick ratio of 2.87 and a debt-to-equity ratio of 1.01.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.03. Antares Pharma had a negative return on equity of 9.67% and a negative net margin of 4.03%. The firm had revenue of $28.43 million for the quarter, compared to analyst estimates of $21.66 million. As a group, sell-side analysts forecast that Antares Pharma will post -0.08 EPS for the current year.

A number of equities research analysts have commented on ATRS shares. BidaskClub upgraded Antares Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $4.50 price target on shares of Antares Pharma in a research report on Monday, May 6th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $4.83.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Further Reading: Options Trading – Understanding Strike Price

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.